Open Access
Issue
Published:
28 July 2022
Use of potentially inappropriate medications for heart failure according to the three sets of heart failure-specific criteria in Thai older patients with heart failure
Download citation
624
Views
63
Downloads
0
Crossref
1
WoS
1
Scopus
0
CSCD
To study the prevalence of potentially inappropriate medications for patients with heart failure (PIMHF) use and to identify factors associated with PIMHF use in Thai older HF patients.
This cross-sectional analytical survey included data on older (≥ 60 years) HF patients obtained from the electronic medical record databases of secondary- and tertiary-care hospitals. The medication profiles of patients were assessed to examine whether they were prescribed any PIMHF after an HF diagnosis. For PIMHF detection, the HF-specific criteria, including 2014 St Vincent criteria, 2019 Beers criteria, and 2021 Thailand criteria were applied. The prevalence of PIMHF use was expressed as percentages. The associated factors were identified using a binary logistic regression analysis, expressed as the adjusted odds ratio (aOR) and 95% confidence interval (95% CI).
A total of 2,639 patients were included in the study. Thirty-two PIMHF were found to have been prescribed to these patients. The prevalence of PIMHF use identified by the ST Vincent criteria, the Beers criteria, the Thailand criteria, and the three combined criteria was 23.76%, 19.67%, 21.18%, and 25.16%, respectively. The factors associated with PIMHF use were secondary-care hospital (aOR = 1.54, 95% CI: 1.26−1.87), HF with preserved ejection fraction (HFpEF) (aOR = 1.81, 95% CI: 1.38−2.38), hypertension (HTN) (aOR = 1.24, 95% CI: 1.02−1.51), diabetes mellitus (DM) (aOR = 1.39, 95% CI: 1.10−1.75), chronic pulmonary diseases (CPD) (aOR = 2.09, 95% CI: 1.56−2.80), and connective tissue diseases (CTD) (aOR = 5.10, 95% CI: 2.20−11.83).
PIMHF are commonly used in Thai older HF patients. The factors associated with PIMHF use identified in this study include secondary-care hospital, HFpEF, HTN, DM, CPD, and CTD.
menu
Use of potentially inappropriate medications for heart failure according to the three sets of heart failure-specific criteria in Thai older patients with heart failure
Abstract
To study the prevalence of potentially inappropriate medications for patients with heart failure (PIMHF) use and to identify factors associated with PIMHF use in Thai older HF patients.
This cross-sectional analytical survey included data on older (≥ 60 years) HF patients obtained from the electronic medical record databases of secondary- and tertiary-care hospitals. The medication profiles of patients were assessed to examine whether they were prescribed any PIMHF after an HF diagnosis. For PIMHF detection, the HF-specific criteria, including 2014 St Vincent criteria, 2019 Beers criteria, and 2021 Thailand criteria were applied. The prevalence of PIMHF use was expressed as percentages. The associated factors were identified using a binary logistic regression analysis, expressed as the adjusted odds ratio (aOR) and 95% confidence interval (95% CI).
A total of 2,639 patients were included in the study. Thirty-two PIMHF were found to have been prescribed to these patients. The prevalence of PIMHF use identified by the ST Vincent criteria, the Beers criteria, the Thailand criteria, and the three combined criteria was 23.76%, 19.67%, 21.18%, and 25.16%, respectively. The factors associated with PIMHF use were secondary-care hospital (aOR = 1.54, 95% CI: 1.26−1.87), HF with preserved ejection fraction (HFpEF) (aOR = 1.81, 95% CI: 1.38−2.38), hypertension (HTN) (aOR = 1.24, 95% CI: 1.02−1.51), diabetes mellitus (DM) (aOR = 1.39, 95% CI: 1.10−1.75), chronic pulmonary diseases (CPD) (aOR = 2.09, 95% CI: 1.56−2.80), and connective tissue diseases (CTD) (aOR = 5.10, 95% CI: 2.20−11.83).
PIMHF are commonly used in Thai older HF patients. The factors associated with PIMHF use identified in this study include secondary-care hospital, HFpEF, HTN, DM, CPD, and CTD.
References(38)
Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. Circulation 2020; 141: E139−E596.
Jenghua K, Jedsadayanmata A. Rate and predictors of early readmission among Thai patients with heart failure. J Med Assoc Thai 2011; 94: 782−788.
Laothavorn P, Hengrussamee K, Kanjanavanit R, et al. Thai Acute Decompensated Heart Failure Registry (Thai ADHERE). CVD Prev Control 2010; 5: 89−95.
Díez-Villanueva P, Alfonso F. Heart failure in the elderly. J Geriatr Cardiol 2016; 13: 115−117.
Davis JD, Olsen MA, Bommarito K, et al. All-Payer Analysis of Heart Failure Hospitalization 30-Day Readmission: Comorbidities Matter. Am J Med 2017; 130: 93.e9−28.
Van Deursen VM, Urso R, Laroche C, et al. Co-morbidities in patients with heart failure: An analysis of the European heart Failure Pilot Survey. Eur J Heart Fail 2014; 16: 103−111.
Khan MS, Samman Tahhan A, et al. Trends in prevalence of comorbidities in heart failure clinical trials. Eur J Heart Fail 2020; 22: 1032−1042.
Unlu O, Levitan EB, Reshetnyak E, et al. Polypharmacy in older adults hospitalized for heart failure. Circ Hear Fail 2020; 13: 577−588.
Dunlay SM, Eveleth JM, Shah ND, et al. Medication adherence among community-dwelling patients with heart failure. Mayo Clin Proc 2011; 86: 273−281.
Kennel PJ, Kneifati-Hayek J, Bryan J, et al. Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES). BMC Cardiovasc Disord 2019; 19: 76.
Bermingham M, Ryder M, Travers B, et al. The St Vincent’s potentially inappropriate medicines study: Development of a disease-specific consensus list and its evaluation in ambulatory heart failure care. Eur J Heart Fail 2014; 16: 915−922.
Panel B the 2019 AGSBCUE. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2019; 67: 674−694.
Jenghua K, Chinwong S, Chinwong D, Kanjanarat P. Development of a list of potentially inappropriate medications for patients with heart failure (PIMHF). Res Soc Adm Pharm 2021; 17: 894−903.
Zahwe M, Skouri H, Rachidi S, et al. Potentially inappropriate medications in elderly patients with heart failure: Beers Criteria-based study. Int J Pharm Pract 2020; 28: 652−659.
Jenghua K. Prevalence and associated factors of potentially inappropriate medications among Thai patients with heart failure. Int J Clin Pract 2021; 75: 1−9.
Prasert V, Akazawa M, Shono A, Chanjaruporn F, et al. Applying the Lists of Risk Drugs for Thai Elderly (LRDTE) as a mechanism to account for patient age and medicine severity in assessing potentially inappropriate medication use. Res Soc Adm Pharm 2018; 14: 451−458.
Knodel J, Chayovan N. Older persons in Thailand: a demographic, social and economic profile. Ageing Int 2008; 33: 3−14.
Saczynski JS, Andrade SE, Harrold LR, et al. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Safe 2012; 21: 129−140.
Ariyachaipanich A, Krittayaphong R, Kunjara N, et al. Heart Failure Council of Thailand (HFCT) 2019 Heart Failure Guideline: Introduction and Diagnosis. J Med Assoc Thai 2019; 102: 231−239.
Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373−383.
Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130−1139.
Buakhamsri A, Chirakarnjanakorn S, Sanguanwong S, et al. Heart Failure Council of Thailand (HFCT) 2019 heart failure guideline: pharmacologic treatment of chronic heart failure-part I. J Med Assoc Thai 2019; 102: 240−244.
Yingchoncharoen T, Kanjanavanich R. Heart Failure Council of Thailand (HFCT) 2019 heart failure guideline: pharmacologic treatment of chronic heart failure-part II. J Med Assoc Thail 2019; 102: 368−372.
Petrovic M, O’Mahony D, Cherubini A. Inappropriate prescribing: hazards and solutions. Age Ageing 2022; 51: afab269.
Page RL, O’Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation 2016; 134: e32−e69.
Senaviratna N, Cooray T. Diagnosing multicollinearity of logistic regression model. Asian J Probab Stat 2019: 1−9.
Jaber D, Vargas F, Nguyen L, et al. Prescriptions for potentially inappropriate medications from the beers criteria among older adults hospitalized for heart failure. J Card Fail 2022; 28: 906−915.
Rotunno R, Oppo I, Saetta G, et al. NSAIDs and heart failure: A dangerous relationship. Monaldi Arch Chest Dis 2018; 88: 950.
Huang SP, Wen YC, Huang ST, et al. Nonsteroidal anti-inflammatory drugs and risk of first hospitalization for heart failure in patients with no history of heart failure: a population-based case-crossover study. Drug Safe 2019; 42: 67−75.
Schjerning A-M, McGettigan P, Gislason G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol 2020; 17: 574−584.
Chirakarnjanakorn S, Krittayaphong R, Chantrarat T, et al. Heart Failure Council of Thailand (HFCT) 2019 Heart Failure Guideline: comorbidity in heart failure. J Med Assoc Thai 2019; 102: 508−512.
Phrommintikul A, Buakhamsri A, Janwanishstaporn S, et al. Heart Failure Council of Thailand (HFCT) 2019 heart failure guideline: acute heart failure. J Med Assoc Thail 2019; 102: 373−379.
Chongtrakul P. RDU hospital: The pathway to rational drug use. Thai J Pharmacol 2015; 37: 48−62.
Duque ER, Briasoulis A, Alvarez PA. Heart failure with preserved ejection fraction in the elderly: pathophysiology, diagnostic and therapeutic approach. J Geriatr Cardiol 2019; 16: 421.
O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 2014; 44: 213−218.
Publication history
Copyright
Acknowledgements
The authors wish to thank all the hospital staff for their support with data retrieval from the electronic medical record (EMR) database. The authors declare no conflict of interests.
FEEDBACK 
TOP